Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer

Study ID
NCT01729481

Study type
Interventional

Study phase
Phase 2

Study status
Unknown status

Trial Acronym

ML22774

Trial Summary

In the current study it is examined whether patients with good risk factors (age <75 years, total serum bilirubin < 1,5xULN, no history of cardiovascular diseases) treated with gemcitabine and erlotinib who developed skin rash of any grade during the first 4 weeks of treatment have a comparable outcome as patients who receive FOLFIRINOX.

More informations

Trial Starting Date

Jul 31,2012

Requirements

Gender All
Minimum age 18 Years
Maximum age 75 Years

Enrollement Limit

150